Filing Analysis
ProMIS Neurosciences Inc. filed an 8-K to announce the release of its financial results and financial condition for the quarter ended June 30, 2026. The company also scheduled a conference call to discuss these results.
π Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The company issued a press release (Exhibit 99.1) containing financial results.
- A conference call and audio webcast was scheduled for August 13, 2026, at 4:30 PM EST.
ProMIS Neurosciences reported positive blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b trial for PMN310 in Alzheimer's disease. The data suggests a favorable safety profile with no ARIA-E observed, even among high-risk APOE4 carriers.
π© Red Flags
- Data is currently blinded, meaning treatment allocation between drug and placebo groups is not yet known.
- Biomarker trends are preliminary and do not constitute a determination of efficacy.
π Key Facts
- Interim analysis of 136 AD patients showed no cases of amyloid-related imaging abnormalities-edema (ARIA-E).
- Total ARIA rate was 4.4%, consisting only of mild and asymptomatic microhemorrhages (ARIA-H).
- No treatment-related serious adverse events or drug-related discontinuations reported at interim.
- 68.5% of patients showed a decline in plasma pTau217 and 62.5% showed a decline in CSF MTBR-tau243 (blinded observations).
- The trial remains blinded; unblinded topline 12-month data is expected in Q1 2027.
ProMIS Neurosciences Inc. held its 2026 Annual Meeting of Stockholders on May 20, 2026, where shareholders approved an amendment to the 2025 Stock Option and Incentive Plan to increase the share reserve by 900,000 shares. Shareholders also elected seven directors and ratified Baker Tilly US, LLP as the independent auditor for fiscal year 2026.
π© Red Flags
- Potential dilution from the 900,000 share increase to the 2025 Stock Option and Incentive Plan, which represents approximately 10% of the company's 8,967,693 outstanding shares.
π Key Facts
- The Annual Meeting of Stockholders was held on May 20, 2026, with 53.1% of the 8,967,693 outstanding shares represented.
- Shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the shares available for issuance by 900,000.
- Seven director nominees (Eugene Williams, Neil Cashman, Joshua Mandel-Brehm, Maggie Shafmaster, Neil K. Warma, William Wyman, and Slanix Alex) were elected to serve until the 2027 annual meeting.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
ProMIS Neurosciences Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished as an exhibit to the 8-K filing.
π Key Facts
- The company reported financial results for the quarter ended March 31, 2026.
- The press release was issued on May 12, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
ProMIS Neurosciences Inc. reported its financial results for the fiscal year ended December 31, 2025. The announcement was made via a press release furnished with the SEC on March 25, 2026.
π Key Facts
- The filing reports financial condition and results for the full year ended December 31, 2025.
- The information was disclosed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on March 25, 2026, and is included as Exhibit 99.1.
- The company is an emerging growth company listed on the Nasdaq Capital Market under the symbol PMN.
ProMIS Neurosciences entered into a Securities Purchase Agreement to raise approximately $75 million through the sale of common shares and warrants to accredited investors. The offering includes significant warrant components that could result in an additional $100 million in gross proceeds upon exercise.
π© Red Flags
- Significant potential dilution via common shares and warrants (over 13 million total warrant/pre-funded shares).
- Warrant exercise price ($14.40) is significantly higher than the current offering price ($10.77), indicating a heavy incentive for future share issuance.
- Insider participation in the offering at a premium ($12.13) compared to the general PIPE investors ($10.77).
π Key Facts
- Total expected aggregate gross proceeds: ~$75 million (before fees).
- Potential additional gross proceeds of up to $100 million if warrants are fully exercised.
- 6,090,075 common shares sold at $10.77 per share; 725,221 shares sold to affiliates/insiders at $12.13 per share.
- Common Share Warrants: 6,915,296 warrants with an exercise price of $14.40, exercisable immediately and expiring upon a 'Milestone Event' or Feb 3, 2031.
- Pre-Funded Warrants: 100,000 warrants at $10.77 per share (exercise price $0.0001) to be exercised for Common Shares.
- The 'Milestone Event' is defined as the public announcement of topline data from PMN310 single ascending dose cohorts.
- Closing date expected by February 3, 2026.
ProMIS Neurosciences Inc. has regained compliance with the Nasdaq $1.00 minimum bid price requirement. The company successfully maintained a closing price of $1.00 or greater for 10 consecutive business days, resolving a deficiency that had been outstanding since January 2025.
π© Red Flags
- History of delisting risk: The company has been struggling with minimum bid price requirements for nearly a year (since Jan 2025).
- Implicit mention of reverse stock split: The filing notes that a reverse split was part of the compliance strategy, which is often viewed negatively by micro-cap investors.
π Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days from November 28, 2025, to December 11, 2025.
- The deficiency originated on January 8, 2025, due to the stock trading below $1.00.
- The Company had previously been granted an extension until December 29, 2025, to cure the deficiency.
- The company noted that a reverse stock split was considered as a potential method to cure the deficiency.
ProMIS Neurosciences Inc. is implementing a 1-for-25 reverse stock split effective November 28, 2025. The action was approved by stockholders on November 17, 2025, to consolidate outstanding common shares.
π© Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or manage share price).
π Key Facts
- Reverse stock split ratio: 1-for-25.
- Effective date: 12:01 a.m. ET on November 28, 2025.
- New CUSIP number: 74346M505.
- Fractional shares will be settled in cash instead of being issued as stock.
- Trading on Nasdaq will resume on a split-adjusted basis at market open on November 28, 2025, under the symbol 'PMN'.
ProMIS Neurosciences Inc. held a special meeting of shareholders where shareholders approved a proposal for a share consolidation (reverse stock split) with a ratio ranging from 1-for-5 to 1-for-25.
π© Red Flags
- Reverse stock split approved (typically used to boost share price to meet exchange listing requirements).
- High potential for significant dilution or psychological impact on existing shareholders depending on the final ratio chosen by the Board.
π Key Facts
- Special Meeting held on November 17, 2025.
- Shareholders approved the Share Consolidation Proposal with 21,331,321 votes in favor and 2,939,187 against.
- The consolidation ratio is set between 1-for-5 and 1-for-25, at the Board's discretion.
- The consolidation is to be effected within one year from the date of the Special Meeting.
- Quorum was met with approximately 45.21% (24,328,153 shares) of outstanding common shares represented.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results and press release for the periods ended September 30, 2025.
π Key Facts
- The filing reports financial condition and results for the three months and nine months ended September 30, 2025.
- A press release dated November 12, 2025, was issued as Exhibit 99.1.
- The company is an emerging growth company.
ProMIS Neurosciences Inc. announced the appointment of Slanix Paul Alex, Pharm.D., to its Board of Directors, effective October 22, 2025. Dr. Alex is an experienced life sciences investment professional and will serve as an independent director.
π Key Facts
- Slanix Paul Alex, Pharm.D., appointed to the Board on October 22, 2025.
- Dr. Alex is deemed an independent director under Nasdaq listing standards.
- Compensation includes a grant of 40,000 common share options (Initial Award) with 25% vesting immediately and the remainder over 36 months.
- Annual cash fee of $40,000 for service as a director.
- Dr. Alex is eligible for an annual award of 20,000 common shares starting in 2026.
- Equity awards and cash compensation will be attributed to Ally Bridge MedAlpha Master Fund L.P.
ProMIS Neurosciences Inc. entered into an amended and restated employment agreement with its Chief Scientific Officer, Neil Cashman, effective September 26, 2025. The amendment updates his compensation structure, including base salary, bonus targets, and new equity awards.
π© Red Flags
- None identified in this specific filing.
π Key Facts
- Amended Agreement date: September 26, 2025.
- Annual base salary set at $500,000 CAD.
- Discretionary bonus target is 35% of base salary.
- Grant of 165,000 common share options with FMV exercise price.
- Equity Award vesting: 25% on first anniversary; remainder over 36 months.
- Severance provisions include 9 months' salary for termination without cause or change in control.
ProMIS Neurosciences announced that its independent Data and Safety Monitoring Board (DSMB) has unanimously recommended proceeding to the final dose escalation cohort for its lead Alzheimer's candidate, PMN310. The clinical trial is progressing as planned with no safety concerns reported in previous cohorts.
π Key Facts
- DSMB unanimously recommended proceeding to the third and final dose escalation cohort for the PRECISE-AD Phase 1b trial of PMN310.
- No cases of amyloid-related imaging abnormalities (ARIA) have been observed through Cohort 2.
- Cohort 2 is fully enrolled; enrollment for Cohort 3 is underway.
- Company expects to deliver 6-month interim data in Q2 2026.
- Final top-line results are expected in Q4 2026.
ProMIS Neurosciences Inc. entered into an At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $17,988,524 in common shares. This program allows the company to issue equity from time to time at its discretion via a shelf registration statement.
π© Red Flags
- Potential for significant shareholder dilution through the issuance of new common shares.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operations (burn rate management).
π Key Facts
- Entered into an At The Market (ATM) Offering Agreement on August 13, 2025.
- Agent: H.C. Wainwright & Co., LLC.
- Aggregate offering price: up to $17,988,524 in common shares.
- Commission rate: up to 3% of gross sales proceeds.
- Sales will be conducted via a shelf Registration Statement on Form S-3 filed on August 13, 2025.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance via a press release.
π Key Facts
- Reporting period: Three and six months ended June 30, 2025.
- Filing date: August 13, 2025.
- The company is an emerging growth company as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
ProMIS Neurosciences Inc. entered into a PIPE offering to raise approximately $3.0 million in gross proceeds from existing institutional investors through the sale of warrants.
π© Red Flags
- Significant dilution potential due to the issuance of over 15.6 million warrants.
- Low warrant exercise price ($0.1875) relative to the $1.25 strike price suggests a heavily discounted structure typical of distressed financing.
π Key Facts
- The company is raising ~$3.0 million in aggregate gross proceeds via a PIPE offering.
- Warrants issued: 15,616,360 Common Shares at an offering price of $0.1875 per share.
- Exercise price for warrants is set at $1.25 per share.
- Warrants are immediately exercisable and expire in five years.
- Total gross proceeds (including existing warrant exercises) expected to be approximately $12.0 million.
- The company entered into a Registration Rights Agreement requiring an SEC registration statement filing within 45 days of closing.
ProMIS Neurosciences announced two significant capital raising activities on July 22, 2025: a $800k pre-funded warrant offering and a $2.4 million PIPE offering involving warrants with an exercise price of $1.25 per share. Total gross proceeds from these combined offerings and existing warrant exercises are expected to reach approximately $9.2 million.
π© Red Flags
- Significant dilution risk: The PIPE offering involves over 12.6 million warrants, which could lead to substantial share issuance upon exercise.
- Deeply discounted pricing: Pre-funded warrants are being sold at $0.8124 per share, significantly lower than the $1.25 exercise price of the PIPE warrants, suggesting a need for immediate liquidity at unfavorable terms.
- Multiple 8-K items (1.01, 3.02, 8.01) indicating complex capital restructuring/fundraising.
π Key Facts
- Entered into a securities purchase agreement for a pre-funded warrant to issue 984,736 Common Shares at $0.8124 per share (approx. $800,000 gross proceeds).
- Entered into a PIPE Purchase Agreement to raise $2.4 million via the sale of warrants to purchase 12,616,821 Common Shares.
- The PIPE warrants have an exercise price of $1.25 per share and expire in five years.
- Total expected gross proceeds from all combined sources (including existing warrant exercises) is approximately $9.2 million.
- The company entered into a Registration Rights Agreement requiring the filing of a registration statement within 45 days of the PIPE closing.
ProMIS Neurosciences terminated its $25 million At-The-Market (ATM) offering agreement with BTIG, LLC effective July 21, 2025. Concurrently, the company reported positive clinical and regulatory developments regarding its lead Alzheimer's candidate, PMN310.
π© Red Flags
- Termination of a primary liquidity mechanism (ATM program) may indicate the company is seeking alternative financing or has shifted its capital strategy.
- The very low utilization of the ATM ($190k out of $25M) suggests significant difficulty in selling equity into the market via this channel.
π Key Facts
- Termination of ATM Agreement with BTIG, LLC effective July 21, 2025.
- Only $190,274 in gross proceeds had been raised from the $25 million program prior to termination.
- $24.8 million in potential equity dilution via this specific program was cancelled.
- FDA granted Fast Track Designation to PMN310 for Alzheimer's disease treatment.
- PMN310 Phase 1b trial dose escalation approved; no cases of ARIA (brain swelling/microhemorrhages) observed as of July 21, 2025.
ProMIS Neurosciences has received an extension from Nasdaq to regain compliance with the minimum bid price requirement. The company is currently non-compliant but has been granted a second 180-day period, expiring December 29, 2025.
π© Red Flags
- Delisting risk: Failure to meet the $1.00 minimum bid price by Dec 29, 2025, will result in delisting notice.
- Potential for reverse stock split: Management has signaled a reverse split as a likely remedial action.
- Ongoing non-compliance with Nasdaq listing standards.
π Key Facts
- The Company was notified of a deficiency regarding Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- The initial compliance deadline was July 2, 2025.
- Nasdaq has granted an additional 180-day compliance period until December 29, 2025.
- Compliance is contingent on the company meeting stockholder's equity and other listing standards.
- The Company explicitly mentioned that a reverse stock split is being considered as a potential method to regain compliance.
ProMIS Neurosciences Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. Shareholders approved the election of seven directors, ratified Baker Tilly US, LLP as independent auditors for fiscal year 2025, and approved a new 2025 Stock Option and Incentive Plan.
π Key Facts
- Annual Meeting held on June 12, 2025.
- 7 directors were elected to serve until the 2026 annual meeting or successors are duly elected.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for FY ending Dec 31, 2025.
- The 2025 Stock Option and Incentive Plan was approved, replacing the previous 2015 Plan.
- Quorum reached with 16,946,944 Common Shares (approx. 51.84% of 32,689,190 outstanding shares) present or represented by proxy.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results for the three months ended March 31, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance.
π Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 12, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial condition and results of operations.
- Company is an emerging growth company.
ProMIS Neurosciences Inc. filed an 8-K to furnish its annual financial results and press release for the fiscal year ended December 31, 2024.
π Key Facts
- Reporting of financial condition and results as of and for the year ended December 31, 2024.
- Press release issued on March 31, 2025, is attached as Exhibit 99.1.
- The company is an emerging growth company.
ProMIS Neurosciences Inc. issued an 8-K to announce clinical progress regarding its lead drug candidate, PMN310, in the PRECISE-AD Phase 1b trial for Alzheimerβs disease.
π Key Facts
- Announced dosing of multiple patients in the PRECISE-AD Phase 1b clinical trial.
- The trial focuses on the lead drug candidate PMN310 for the treatment of Alzheimer's disease.
- Filing includes a press release (Exhibit 99.1) detailing clinical progress.
ProMIS Neurosciences Inc. announced the separation of its Chief Operating Officer, Gavin T. Malenfant, effective February 14, 2025. Notably, the company has decided to terminate the COO position entirely and does not intend to fill the role.
π© Red Flags
- Elimination of a C-suite role (COO) can signal internal restructuring or cost-cutting measures often seen in companies facing liquidity constraints.
- Departure of a key executive without an immediate successor can create operational gaps during critical development phases.
π Key Facts
- Gavin T. Malenfant separated from the role of Chief Operating Officer on February 14, 2025.
- The separation involves a Separation Agreement including severance benefits in exchange for a release of claims.
- The Company has officially terminated the COO position and will not be seeking a replacement.
ProMIS Neurosciences Inc. filed an 8-K to disclose the posting of an updated corporate presentation on its website. This is a routine regulatory filing used to provide non-binding information to the public.
π Key Facts
- Company posted an updated corporate presentation to its website on January 27, 2025.
- The presentation is attached as Exhibit 99.1.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure).
- Information in the presentation is not considered 'filed' for purposes of Section 18 liability.
ProMIS Neurosciences announced the initiation of its Phase 1b clinical trial (PRECISE-AD) for its lead therapeutic candidate, PMN310, targeting Alzheimer's disease. The study will evaluate safety, tolerability, and pharmacokinetics in 100 patients over a 12-month period.
π© Red Flags
- Forward-looking statements include a cautionary note regarding the company's ability to fund operations and continue as a going concern (standard risk disclosure).
π Key Facts
- Initiation of Phase 1b clinical trial (PRECISE-AD) for PMN310 in Alzheimer's disease.
- Study involves 100 patients with mild cognitive impairment (Stage 3 AD) or early AD (Stage 4 AD).
- Trial duration is 12 months to assess safety, tolerability, and pharmacokinetics.
- Phase 1a study in healthy volunteers showed favorable safety/tolerability and CSF drug concentrations supporting target engagement.
- Interim data from the Phase 1b trial is anticipated in the first half of 2026.
ProMIS Neurosciences Inc. received a notice from Nasdaq stating its common shares failed to meet the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has an initial 180-day compliance period ending July 2, 2025, to regain compliance.
π© Red Flags
- Delisting notice from Nasdaq (Minimum Bid Price Rule violation).
- Potential for delisting if the stock price does not recover to $1.00 for 10 consecutive trading days within the compliance period.
- Risk of being moved to a different exchange or losing liquidity if delisting occurs.
π Key Facts
- Received written notice from Nasdaq on January 3, 2025.
- Failure to comply with the $1 minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)).
- The deficiency is based on the closing bid price for the 30 consecutive trading days prior to the notice.
- Initial compliance period expires July 2, 2025.
- A second 180-day compliance period may be available if certain market value requirements are met.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results for the three and nine months ended September 30, 2024 via a press release.
π Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Filing date: November 14, 2024.
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
ProMIS Neurosciences Inc. held a special meeting of shareholders on October 23, 2024, to vote on the approval of common shares underlying warrants from a previous private placement. Shareholders approved the issuance of shares related to Tranche A and Tranche B purchase warrants.
π© Red Flags
- The need for shareholder approval to comply with Nasdaq Listing Rule 5635(d) indicates potential dilution from previously issued warrants.
- Low quorum participation (45.17%) suggests potentially fragmented or disengaged shareholder base.
π Key Facts
- Special Meeting held on October 23, 2024.
- Proposal No. 1: Approval for potential issuance of Common Shares underlying Tranche A and Tranche B purchase warrants from the July 31, 2024 private placement to comply with Nasdaq Listing Rule 5635(d).
- Proposal No. 1 Result: Approved (8,948,590 votes in favor vs. 121,116 against).
- Quorum present represented approximately 45.17% of outstanding shares (9,093,432 shares).
- Proposal No. 2: Adjournment of the meeting was approved but deemed unnecessary as a quorum and sufficient votes were reached.
ProMIS Neurosciences Inc. has officially appointed Neil Warma as President and Chief Executive Officer, effective August 1, 2024, transitioning him from his interim role held since December 2023.
π© Red Flags
- High performance-based equity incentive (Performance Award) tied to significant stock price appreciation (3x exercise price).
π Key Facts
- Neil Warma appointed CEO effective August 1, 2024; he will also remain on the Board of Directors.
- CEO Employment Agreement includes an annual base salary of $500,000 and a target discretionary bonus of 50% ($250,000).
- Initial Award: Option to purchase 1,144,122 common shares at an exercise price of $1.15 per share (25% vested immediately, remainder over 36 months).
- Performance Award: Option to purchase 490,338 common shares at $1.15/share, vesting if the 10-day VWAP exceeds three times the exercise price.
- Severance terms include 12 months' salary for termination without cause and 18 months' salary for a change in control.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results for the three and six months ended June 30, 2024. The filing serves as a formal announcement of the company's recent operational performance via a press release.
π Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- The company issued a press release on August 8, 2024, containing financial results.
- Neil Warma serves as the Interim Chief Executive Officer.
ProMIS Neurosciences Inc. has regained compliance with the NASDAQ Market Value of Listed Securities Standard after meeting the $35 million minimum requirement for at least 10 consecutive business days.
π© Red Flags
- Previous non-compliance with Nasdaq's minimum market value requirement indicates historical volatility or liquidity issues.
π Key Facts
- The Company received written notification from NASDAQ on July 22, 2024, confirming compliance.
- Compliance was met by maintaining a closing market value of common shares of $35 million or greater for at least 10 consecutive business days between July 8, 2024, and July 19, 2024.
- The NASDAQ Listing Qualifications Staff has officially closed the matter regarding the violation of Rule 5550(b)(2).
ProMIS Neurosciences Inc. entered into a Unit Purchase Agreement to raise $30.3 million in gross proceeds through the sale of common share units and pre-funded units to accredited investors. The offering includes multiple tranches of warrants tied to clinical milestone events and requires shareholder approval for certain warrant exercises.
π© Red Flags
- Significant potential dilution due to the issuance of millions of warrants (Tranche A, B, and C) which could add up to $92.4 million in additional shares.
- Warrant exercise prices ($2.02 - $2.50) are structured around clinical data milestones, creating high volatility linked to trial results.
- Mandatory conversion of Series 2 Preferred Shares into common stock will increase the total share count significantly.
π Key Facts
- Total expected gross proceeds: $30.3 million from initial offering, with potential for up to an additional $92.4 million if all warrants are exercised.
- Units consist of common shares and three tranches of warrants (Tranche A, B, and C).
- Tranche A and B warrants have an exercise price of $2.02 and are subject to shareholder approval per Nasdaq Listing Rule 5635(d).
- Tranche A/B milestones are tied to the public announcement of 6-month and 12-month data for PMN310 cohorts.
- The offering triggers a mandatory conversion of all outstanding Series 2 Preferred Shares into common shares.
- Closing date is expected to be July 31, 2024.
ProMIS Neurosciences announced positive top-line data from the first four cohorts of its Phase 1a clinical trial for PMN310. The drug was well-tolerated in healthy volunteers, showing dose proportionality and a long half-life in cerebrospinal fluid.
π© Red Flags
- Forward-looking statements include a standard risk disclosure regarding the company's ability to fund operations and continue as a going concern.
π Key Facts
- Phase 1a study (NCT06105528) evaluated safety and PK of intravenous PMN310 in healthy volunteers.
- First four single-ascending dose (SAD) cohorts completed: 2.5, 5, 10, and 20 mg/kg.
- No treatment-emergent serious adverse events (SAEs) were observed.
- PMN310 showed dose proportionality in CSF at days 3 and 29.
- CSF levels reached a >100-fold molar excess compared to expected oligomer levels.
- Half-life of PMN310 in CSF was approximately 25 days, supporting once-monthly dosing.
- The fifth and final cohort is undergoing final analysis; full dataset presentation expected in H2 2024.
ProMIS Neurosciences Inc. received a notice from Nasdaq stating it is non-compliant with the minimum Market Value of Listed Securities (MVLS) requirement. The company has until December 29, 2024, to regain compliance by maintaining an MVLS of at least $35 million for a specified period.
π© Red Flags
- Delisting notice from Nasdaq
- Failure to meet market capitalization requirements (MVLS)
- Risk of delisting if compliance is not met by year-end 2024
π Key Facts
- Received notice from Nasdaq on July 2, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(b)(2) regarding minimum Market Value of Listed Securities (MVLS).
- The company failed to maintain an MVLS of at least $35 million for the last 30 consecutive business days.
- Compliance period expires on December 29, 2024.
- To regain compliance, the MVLS must be at least $35 million for a minimum of ten consecutive business days.
ProMIS Neurosciences Inc. held its 2024 annual meeting of shareholders on June 13, 2024. Shareholders approved the election of seven directors, authorized changes to the number of directors, ratified the appointment of Baker Tilly US, LLP as independent auditors, and approved unallocated stock options.
π© Red Flags
- Low quorum participation (approx. 41.19%) may indicate lower shareholder engagement.
π Key Facts
- Annual Meeting held on June 13, 2024.
- Quorum reached with 7,811,371 Common Shares (approx. 41.19%) present or represented by proxy out of 18,961,116 total outstanding shares.
- All seven director nominees were elected to serve until the 2025 annual meeting.
- Proposal 2: Shareholders approved authorization for directors to set the number of directors via resolution (7,406,478 votes in favor).
- Proposal 3: Ratification of Baker Tilly US, LLP as independent registered public accounting firm for FY ending Dec 31, 2024.
- Proposal 4: Approval of unallocated stock options under the Company's stock option plan was passed.
ProMIS Neurosciences Inc. filed an 8-K to furnish its quarterly financial results for the three months ended March 31, 2024 via a press release.
π Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 14, 2024.
- The filing is a standard disclosure of results of operations and financial condition under Item 2.02.
ProMIS Neurosciences issued a press release regarding a scientific paper published in bioRxiv concerning the binding profile of amyloid-beta (AΞ²)-directed antibodies. The study highlights that their lead candidate, PMN310, shows high selectivity for toxic soluble oligomers and avoids binding to plaque/vascular deposits, potentially reducing risks like brain edema.
π© Red Flags
- Forward-looking statements include a standard risk disclosure regarding the 'Companyβs ability to fund its operations and continue as a going concern'.
π Key Facts
- Published a paper in bioRxiv titled 'Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies'.
- PMN310 demonstrated high resistance to monomer competition compared to other tested antibodies.
- The study suggests PMN310 may avoid binding to plaque and vascular deposits, potentially reducing the risk of ARIA-E (brain edema) and ARIA-H (microhemorrhages).
- Murine studies showed no detectable brain hemorrhages after 26 weeks of high-dose (800 mg/kg) weekly dosing.
- PMN310 is currently in Phase 1a clinical studies; safety and pharmacokinetic data are expected in mid-2024.
ProMIS Neurosciences Inc. filed an 8-K to furnish its annual financial results for the fiscal year ended December 31, 2023, via a press release.
π Key Facts
- The filing is a standard disclosure of annual financial results (Item 2.02).
- Reporting period covers the year ended December 31, 2023.
- Results were released via press release on April 1, 2024.
ProMIS Neurosciences entered into an At-The-Market (ATM) offering agreement with BTIG, LLC to sell up to $25.0 million in common stock. This allows the company to raise capital incrementally through various trading methods on Nasdaq.
π© Red Flags
- Potential for immediate share dilution as the company may sell shares at its discretion based on market conditions.
π Key Facts
- Entered into an At The Market Offering Agreement with BTIG, LLC on January 5, 2024.
- Aggregate offering price of up to $25.0 million in common shares.
- The offering is conducted under a previously effective shelf Registration Statement (Form S-3) from September 29, 2023.
- Agent (BTIG, LLC) will receive a commission of up to 3% of gross sales proceeds.
- Sales can be executed via any method permitted by law, including through Nasdaq.
ProMIS Neurosciences Inc. announced a leadership transition effective December 30, 2023, involving the departure of CEO Gail Farfel and the appointment of Neil Warma as interim CEO.
π© Red Flags
- Sudden departure of the CEO (Separation Agreement mentioned).
- Appointment is for an 'interim' CEO, which often suggests a transitional period or search for permanent leadership.
π Key Facts
- Gail Farfel, Ph.D. departed as President, CEO, and Board member effective Dec 30, 2023.
- Neil Warma appointed as interim President and CEO, effective Dec 30, 2023.
- Warma's compensation includes a $250,000 annual base salary and up to $400,000 in milestone-based cash bonuses.
- Warma was granted stock options for 200,000 shares of common stock.
- Warma resigned from his roles on the Compensation Committee and Audit Committee to assume the CEO position.